Your browser doesn't support javascript.
loading
Multiple Sclerosis and the Cancer Diagnosis: Diagnostic Route, Cancer Stage, and the Diagnostic Interval in Breast and Colorectal Cancer.
Groome, Patti A; Webber, Colleen; Maxwell, Colleen J; McClintock, Chad; Seitz, Dallas; Mahar, Alyson; Marrie, Ruth Ann.
Afiliação
  • Groome PA; From ICES Queen's (P.A.G., C.M., D.S., A.M.) and Division of Cancer Care and Epidemiology, Cancer Research Institute (P.A.G.), Queen's University, Kingston; Ottawa Hospital Research Institute (C.W.); Bruyère Research Institute (C.W.), Ottawa; ICES (C.J.M.), Toronto; Schools of Pharmacy and Public He
  • Webber C; From ICES Queen's (P.A.G., C.M., D.S., A.M.) and Division of Cancer Care and Epidemiology, Cancer Research Institute (P.A.G.), Queen's University, Kingston; Ottawa Hospital Research Institute (C.W.); Bruyère Research Institute (C.W.), Ottawa; ICES (C.J.M.), Toronto; Schools of Pharmacy and Public He
  • Maxwell CJ; From ICES Queen's (P.A.G., C.M., D.S., A.M.) and Division of Cancer Care and Epidemiology, Cancer Research Institute (P.A.G.), Queen's University, Kingston; Ottawa Hospital Research Institute (C.W.); Bruyère Research Institute (C.W.), Ottawa; ICES (C.J.M.), Toronto; Schools of Pharmacy and Public He
  • McClintock C; From ICES Queen's (P.A.G., C.M., D.S., A.M.) and Division of Cancer Care and Epidemiology, Cancer Research Institute (P.A.G.), Queen's University, Kingston; Ottawa Hospital Research Institute (C.W.); Bruyère Research Institute (C.W.), Ottawa; ICES (C.J.M.), Toronto; Schools of Pharmacy and Public He
  • Seitz D; From ICES Queen's (P.A.G., C.M., D.S., A.M.) and Division of Cancer Care and Epidemiology, Cancer Research Institute (P.A.G.), Queen's University, Kingston; Ottawa Hospital Research Institute (C.W.); Bruyère Research Institute (C.W.), Ottawa; ICES (C.J.M.), Toronto; Schools of Pharmacy and Public He
  • Mahar A; From ICES Queen's (P.A.G., C.M., D.S., A.M.) and Division of Cancer Care and Epidemiology, Cancer Research Institute (P.A.G.), Queen's University, Kingston; Ottawa Hospital Research Institute (C.W.); Bruyère Research Institute (C.W.), Ottawa; ICES (C.J.M.), Toronto; Schools of Pharmacy and Public He
  • Marrie RA; From ICES Queen's (P.A.G., C.M., D.S., A.M.) and Division of Cancer Care and Epidemiology, Cancer Research Institute (P.A.G.), Queen's University, Kingston; Ottawa Hospital Research Institute (C.W.); Bruyère Research Institute (C.W.), Ottawa; ICES (C.J.M.), Toronto; Schools of Pharmacy and Public He
Neurology ; 98(18): e1798-e1809, 2022 05 03.
Article em En | MEDLINE | ID: mdl-35501160
ABSTRACT
BACKGROUND AND

OBJECTIVES:

The multiple sclerosis (MS) population's survival from breast cancer and colorectal cancer is compromised. Cancer screening and timely diagnoses affect cancer survival and have not been studied in the MS cancer population. We investigated whether the diagnostic route, cancer stage, or diagnostic interval differed in patients with cancer with and without MS.

METHODS:

We conducted a matched population-based cross-sectional study of breast cancers (2007-2015) and colorectal cancers (2009-2012) in patients with MS from Ontario, Canada, using administrative data. Exclusion criteria included second or concurrent primary cancers, no health care coverage, and, for the patients without MS, those with any demyelinating disease. We based 14 matching of MS to non-MS on birth year, sex (colorectal only), postal code, and cancer diagnosis year (breast only). Cancer outcomes were diagnostic route (screen-detected vs symptomatic), stage (stage I vs all others), and diagnostic interval (time from first presentation to diagnosis). Multivariable regression analyses controlled for age, sex (colorectal only), diagnosis year, income quintile, urban/rural residence, and comorbidity.

RESULTS:

We included 351 patients with MS and breast cancer, 1,404 matched patients with breast cancer without MS, 54 patients with MS and colorectal cancer, and 216 matched patients with colorectal cancer without MS. MS was associated with fewer screen-detected cancers in breast (odds ratio [OR] 0.68 [95% CI 0.52, 0.88]) and possibly colorectal (0.52 [0.21, 1.28]) cancer. MS was not associated with differences in breast cancer stage at diagnosis (stage I cancer, OR 0.81 [0.64, 1.04]). MS was associated with greater odds of stage I colorectal cancer (OR 2.11 [1.03, 4.30]). The median length of the diagnostic interval did not vary between people with and without MS in either the breast or colorectal cancer cohorts. Controlling for disability status attenuated some findings.

DISCUSSION:

Breast cancers were less likely to be detected through screening and colorectal cancer more likely to be detected at early stage in people with MS than without MS. MS-related disability may prevent people from getting mammograms and colonoscopies. Understanding the pathways to earlier detection in both cancers is critical to developing and planning interventions to ameliorate outcomes for people with MS and cancer.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Neoplasias Colorretais / Esclerose Múltipla Tipo de estudo: Diagnostic_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Female / Humans País/Região como assunto: America do norte Idioma: En Revista: Neurology Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Neoplasias Colorretais / Esclerose Múltipla Tipo de estudo: Diagnostic_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Female / Humans País/Região como assunto: America do norte Idioma: En Revista: Neurology Ano de publicação: 2022 Tipo de documento: Article